California Cancer Reporting System Standards Volume I: Abstracting and Coding Procedures for Hospitals
Collaborative Stage Metastatic Disease at Diagnosis - Bone.
For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, CS Mets at DX - Bone identifies the presence of discontinuous or distant metastatic involvement of bone at time of diagnosis. This includes only bone, not bone marrow. This data item is required by the CCR.
The presence of metastatic bone disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Stage Data Collection System to derive TNM-M codes and SEER Summary Stage codes for some sites.
The codes are:
Code |
Description |
0 |
No distant (discontinuous) metastases identified either clinically or pathologically, negative findings on imaging reports, or metastases other than bone identified |
1 |
Distant (discontinuous) metastases identified clinically or pathologically, or if primary site is bone and there are metastases in different bone or bones. |
8 |
CS Mets at DX is coded as 98 (not applicable for site). Not applicable sites include hematopoietic, reticuloendothelial, immunoproliferative and myeloproliferative neoplasms, Hodgkin and non-Hodgkin lymphoma, Kaposi sarcoma, other and ill-defined primary sites, unknown primary site. |
9 |
CS Mets at Dx is coded to 99. There are known distant metastases but it is not known whether the distant metastases include bone. |
For additional coding instructions refer to Collaborative Stage Data Collection System Manual and Coding Instructions.